Abstract
The purpose of this study was to assess the rapidity of symptom relief and 4-week efficacy of rabeprazole 20 mg in patients with moderately severe nonerosive gastroesophageal reflux disease. Data were analyzed from 2 similarly designed, double-blind, placebo-controlled, multicenter, U.S. trials. After a 2-week placebo run-in period, patients (N = 261) were randomized to 4 weeks of rabeprazole 20 mg once daily or placebo. Patients kept symptom diaries and scored symptom severity. Median time to first 24-hour heartburn-free interval was 3.5 days for the rabeprazole group compared with 19.5 days for the placebo group (P ≤ .0002). Complete heartburn relief at week 4 was 32% with rabeprazole and 3.8% with placebo (P ≤ .001). Rabeprazole also significantly improved other GERD-associated symptoms (e.g., regurgitation, belching, early satiety) by week 4 compared with placebo (P ≤ .05). Rabeprazole provides fast and potent relief from heartburn and other symptoms of nonerosive gastroesophageal reflux disease.
Similar content being viewed by others
References
A Gallup Organization National Survey: Heartburn across America. Princeton, NJ, Gallup Organization, 1988
Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd: Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 112:1448–1456, 1997
Lind T, Havelund T, Carlsson R, et al.: Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 32:974–979, 1997
Jones T: Can we alter the cytokine balance in the management of infectious diseases? Braz J Infect Dis 1:149–150, 1997
Galmiche JP, Barthelemy P, Hamelin B: Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 11:765–773, 1997
Smout AJ: Endoscopy-negative acid reflux disease. Aliment Pharmacol Ther 22:81–85, 1997
Havelund T, Lind T, Wiklund I, et al.: Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am J Gastroenterol 94:1782–1789, 1999
Revicki DA, Wood M, Maton PN, Sorensen S: The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 104:252–258, 1998
Clouse RE, Richter JE, Heading RC, Janssens J, Wilson JA: Functional esophageal disorders. Gut 45(Suppl 2):II31–II36, 1999
Masclee AA, de Best AC, de Graaf R, Cluysenaer OJ, Jansen JB: Ambulatory 24-hour pH-metry in the diagnosis of gastroesophageal reflux disease. Determination of criteria and relation to endoscopy. Scand J Gastroenterol 25:225–230, 1990
Mattioli S, Pilotti V, Spangaro M, et al.: Reliability of 24-hour home esophageal pH monitoring in diagnosis of gastroesophageal reflux. Dig Dis Sci 34:71–78, 1989
Baldi F, Ferrarini F, Longanesi A, Ragazzini M, Barbara L: Acid gastroesophageal reflux and symptom occurrence. Analysis of some factors influencing their association. Dig Dis Sci 34:1890–1893, 1989
Wiener GJ, Richter JE, Copper JB, Wu WC, Castell DO: The symptom index: a clinically important parameter of ambulatory 24-hour esophageal pH monitoring. Am J Gastroenterol 83:358–361, 1988
Breumelhof R, Smout AJ: The symptom sensitivity index: a valuable additional parameter in 24-hour esophageal pH recording. Am J Gastroenterol 86:160–164, 1991
Weusten BL, Roelofs JM, Akkermans LM, Van Berge-Henegouwen GP, Smout AJ: The symptom-association probability: an improved method for symptom analysis of 24-hour esophageal pH data. Gastroenterology 107:1741–1745, 1994
Williams MP, Sercombe J, Hamilton MI, Pounder RE: A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 12:1079–1089, 1998
Cloud ML, Enas N, Humphries TJ, Bassion S: Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group. Dig Dis Sci 43:993–1000, 1998
Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ: Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. Aliment Pharmacol Ther 13:49–57, 1999
Thjodleifsson B, Beker JA, Dekkers C, Bjaaland T, Finnegan V, Humphries TJ: Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group. Dig Dis Sci 45:845–853, 2000
Miner P Jr, Orr W, Filippone J, Jokubaitis L, Sloan S: Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol 97:1332–1339, 2002
Johanson J, Miner P, Jokubaitis L, Mao L, Sloan S: Rabeprazole significantly improves heartburn vs placebo in endoscopically negative GERD patients with moderate to severe symptoms [abstract]. Am J Gastroenterol 96(Suppl):S18, 2001
Bate CM, Griffin SM, Keeling PW, et al.: Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther 10:547–555, 1996
Storr M, Meining A, Allescher HD: Pathophysiology and pharmacological treatment of gastroesophageal reflux disease. Dig Dis 18:93–102, 2000
Soll AH, Fass R: Gastroesophageal reflux: practical management of a common, challenging disorder. Clin Cornerstone 1:1–17, 1999
Lambert R: Review article: current practice and future perspectives in the management of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 11:651–662, 1997
Freston JW, Malagelada JR, Petersen H, McCloy RF: Critical issues in the management of gastroesophageal reflux disease. Eur J Gastroenterol Hepatol 7:577–586, 1995
Sanders SW: Pathogenesis and treatment of acid peptic disorders: comparison of proton pump inhibitors with other antiulcer agents. Clin Ther 18:2–34, 31, 1996
Bruley des Varannes S, Galmiche JP: Evaluation of Esophageal Sensitivity, vol. 22. Basel, Karger, 1994
Pehlivanov N, Liu J, Mittal R: Sustained esophageal contraction: a motor correlate of heartburn symptom [abstract # G4613]. Gastroenterology 116:1999
Trimble KC, Pryde A, Heading RC: Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut 37:7–12, 1995
Meyer JH, Lembo A, Elashoff JD, Fass R, Mayer EA: Duodenal fat intensifies the perception of heartburn. Gut 49:624–628, 2001
Carlsson R, Dent J, Watts R, et al: Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 10:119–124, 1998
Katz PO, Castell DO, Levine D: Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther 18:875–882, 2003
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by Eisai Inc., Teaneck, New Jersey, and Janssen Pharmaceutica Inc., Titusville, New Jersey.
Rights and permissions
About this article
Cite this article
Kahrilas, P.J., Miner, P., Johanson, J. et al. Efficacy of Rabeprazole in the Treatment of Symptomatic Gastroesophageal Reflux Disease. Dig Dis Sci 50, 2009–2018 (2005). https://doi.org/10.1007/s10620-005-3000-3
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10620-005-3000-3